1
|
Heywood A, Stocks J, Schneider JA, Arfanakis K, Bennett DA, Beg MF, Wang L. In vivo effect of LATE-NC on integrity of white matter connections to the hippocampus. Alzheimers Dement 2024. [PMID: 38877688 DOI: 10.1002/alz.13808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Revised: 02/20/2024] [Accepted: 02/25/2024] [Indexed: 06/16/2024]
Abstract
INTRODUCTION TAR DNA-binding protein 43 (TDP-43) is a highly prevalent proteinopathy that is involved in neurodegenerative processes, including axonal damage. To date, no ante mortem biomarkers exist for TDP-43, and few studies have directly assessed its impact on neuroimaging measures utilizing pathologic quantification. METHODS Ante mortem diffusion-weighted images were obtained from community-dwelling older adults. Regression models calculated the relationship between post mortem TDP-43 burden and ante mortem fractional anisotropy (FA) within each voxel in connection with the hippocampus, controlling for coexisting Alzheimer's disease and demographics. RESULTS Results revealed a significant negative relationship (false discovery rate [FDR] corrected p < .05) between post mortem TDP-43 and ante mortem FA in one cluster within the left medial temporal lobe connecting to the parahippocampal cortex, entorhinal cortex, and cingulate, aligning with the ventral subdivision of the cingulum. FA within this cluster was associated with cognition. DISCUSSION Greater TDP-43 burden is associated with lower FA within the limbic system, which may contribute to impairment in learning and memory. HIGHLIGHTS Post mortem TDP-43 pathological burden is associated with reduced ante mortem fractional anisotropy. Reduced FA located in the parahippocampal portion of the cingulum. FA in this area was associated with reduced episodic and semantic memory. FA in this area was associated with increased inward hippocampal surface deformation.
Collapse
Affiliation(s)
- Ashley Heywood
- Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Jane Stocks
- Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Julie A Schneider
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA
- Department of Pathology, Rush University Medical Center, Chicago, Illinois, USA
| | - Konstantinos Arfanakis
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA
- Department of Biomedical Engineering, Illinois Institute of Technology, Suite, Chicago, Illinois, USA
- Department of Diagnostic Radiology, Rush University Medical Center, Chicago, Illinois, USA
| | - David A Bennett
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA
| | - Mirza Faisal Beg
- Simon Fraser University, School of Engineering Science, 8888 University Drive, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Lei Wang
- Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
- Department of Psychiatry and Behavioral Health, Ohio State University College of Medicine, Columbus, Ohio, USA
| |
Collapse
|
2
|
Bourbon-Teles J, Jorge L, Canário N, Martins R, Santana I, Castelo-Branco M. Associations between cortical β-amyloid burden, fornix microstructure and cognitive processing of faces, places, bodies and other visual objects in early Alzheimer's disease. Hippocampus 2023; 33:112-124. [PMID: 36578233 DOI: 10.1002/hipo.23493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 11/10/2022] [Accepted: 12/04/2022] [Indexed: 12/30/2022]
Abstract
Using two imaging modalities, that is, Pittsburgh compound B (PiB) positron emission tomography (PET) and diffusion tensor imaging (DTI) the present study tested associations between cortical amyloid-beta (Aβ) burden and fornix microstructural changes with cognitive deficits in early Alzheimer's disease (AD), namely deficits in working memory (1-back) processing of visual object categories (faces, places, objects, bodies and verbal material). Second, we examined cortical Aβ associations with fornix microstructure. Seventeen early AD patients and 17 healthy-matched controls were included. Constrained spherical deconvolution-based tractography was used to segment the fornix and a control tract the central branch of the superior longitudinal fasciculus (CB-SLF) previously implicated in working memory processes. Standard uptake value ratios (SUVR) of Aβ were extracted from 45 cortical/subcortical regions from the AAL atlas and subject to principal component analysis for data reduction. Patients exhibited (i) impairments in cognitive performance (ii) reductions in fornix fractional anisotropy (FA) and (iii) increases in a component that loaded highly on cortical Aβ. There were no group differences in CB-SLF FA and in a component loading highly on subcortical Aβ. Partial correlation analysis in the patient group showed (i) positive associations between fornix FA and performance for all the visual object categories and (ii) a negative association between the cortical Aβ component and performance for the object categories but not for the remaining classes of visual stimuli. A subsequent analysis showed a positive association between overall cognition (performance across distinct 1-back task conditions) with fornix FA but no association with cortical Aβ burden, in keeping with influential accounts on early onset AD. This indicates that the fornix degenerates early in AD and contributes to deficits in working memory processing of visual object categories; though it is also important to acknowledge the importance of prospective longitudinal studies with larger samples. Overall, the effect sizes of fornical degeneration on visual working memory appeared stronger than the ones related to amyloid burden.
Collapse
Affiliation(s)
- José Bourbon-Teles
- HEI-Lab, Lusófona University, Lisbon, Portugal.,Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.,Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Lília Jorge
- Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.,Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Nádia Canário
- Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.,Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Ricardo Martins
- Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal
| | - Isabel Santana
- Department of Neurology, Coimbra University Hospital, Coimbra, Portugal
| | - Miguel Castelo-Branco
- Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.,Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| |
Collapse
|
3
|
Rabin JS, Pruzin J, Scott M, Yang HS, Hampton O, Hsieh S, Schultz AP, Buckley RF, Hedden T, Rentz D, Johnson KA, Sperling RA, Chhatwal JP. Association of β-Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy. Neurology 2022; 99:e270-e280. [PMID: 35473760 PMCID: PMC9302937 DOI: 10.1212/wnl.0000000000200551] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 03/02/2022] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Vascular risk factors and elevated β-amyloid (Aβ) are commonly observed together among older adults. Here, we examined the interactive vs independent effects of systemic vascular risk and Aβ burden on longitudinal gray matter atrophy and how their co-occurrence may be related to cognitive decline in a cohort of clinically normal adults. A secondary goal was to examine whether vascular risk influences gray matter atrophy independently from markers of white matter injury. METHODS Participants were 196 adults (age 73.8 ± 6.1 years) from the Harvard Aging Brain Study. Baseline Aβ burden was quantified with Pittsburgh compound B PET. Baseline vascular risk was measured with the Framingham Heart Study cardiovascular disease risk score. Brain atrophy was quantified longitudinally with structural MRI over a median of 4.50 (±1.26) years. Cognition was assessed yearly with the Preclinical Alzheimer Cognitive Composite over a median of 6.25 (±1.40) years. Linear mixed-effects models examined vascular risk and Aβ burden as interactive vs independent predictors of gray matter atrophy, with adjustment for age, sex, years of education, APOE ε4 status, intracranial volume (when appropriate), and their interactions with time. In subsequent models, we adjusted for markers of white matter injury to determine whether vascular risk accelerated brain atrophy independently from diffusion- and fluid-attenuated inversion recovery (FLAIR)-based markers. Mediation analyses examined whether brain atrophy mediated the interactive association of vascular risk and Aβ burden on cognitive decline. RESULTS Higher vascular risk and elevated Aβ burden interacted to predict more severe atrophy in frontal and temporal lobes, thalamus, and striatum. Higher Aβ burden, but not vascular risk, was associated with more severe atrophy in parietal and occipital lobes, as well as the hippocampus. Adjusting for diffusion- and FLAIR-based markers of white matter injury had little impact on the above associations. Gray matter atrophy mediated the association between vascular risk and cognitive decline at higher levels of Aβ burden. DISCUSSION We observed an interaction between elevated vascular risk and higher Aβ burden with longitudinal brain atrophy, which in turn influenced cognitive decline. These results support vascular risk factor management as a potential intervention to slow neurodegeneration and cognitive decline in preclinical Alzheimer disease.
Collapse
Affiliation(s)
- Jennifer S Rabin
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Jeremy Pruzin
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Matthew Scott
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Hyun-Sik Yang
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Olivia Hampton
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Stephanie Hsieh
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Aaron P Schultz
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Rachel F Buckley
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Trey Hedden
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Dorene Rentz
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Keith A Johnson
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Reisa A Sperling
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Jasmeer P Chhatwal
- From the Department of Psychiatry (J.S.R.), Department of Neurology (J.P., M.S., H.-S.Y., O.H., S.H., A.P.S., R.F.B., D.R., K.A.J., R.A.S., J.P.C.), Department of Radiology (A.P.S., K.A.J., R.A.S.), Athinoula A. Martinos Center for Biomedical Imaging, and Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.S.R.), Division of Neurology, Sunnybrook Health Sciences Centre, and Rehabilitation Sciences Institute (J.S.R.), University of Toronto; Harquail Centre for Neuromodulation (J.S.R.), Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Banner Alzheimer's Institute (J.P.), Phoenix, AZ; Department of Neurology (H.-S.Y., D.R., K.A.J., R.A.S., J.P.C.), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Florey Institute (R.F.B.), and Melbourne School of Psychological Sciences (R.F.B.), University of Melbourne, Australia; and Department of Neurology (T.H.), Icahn School of Medicine at Mount Sinai, New York, NY.
| |
Collapse
|
4
|
Shaikh I, Beaulieu C, Gee M, McCreary CR, Beaudin AE, Valdés-Cabrera D, Smith EE, Camicioli R. Diffusion tensor tractography of the fornix in cerebral amyloid angiopathy, mild cognitive impairment and Alzheimer's disease. Neuroimage Clin 2022; 34:103002. [PMID: 35413649 PMCID: PMC9010796 DOI: 10.1016/j.nicl.2022.103002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 03/26/2022] [Accepted: 04/02/2022] [Indexed: 11/16/2022]
Abstract
The fornix was delineated with deterministic tractography from diffusion tensor images (DTI). Fornix diffusion changes were found in the fornix in CAA, AD and MCI compared to controls. Higher fornix diffusivity correlated with smaller hippocampal volume and larger ventricles. Fornix diffusion measures correlated with cognitive measures in the combined disease groups.
Purpose Cerebral amyloid angiopathy (CAA) is a common neuropathological finding and clinical entity that occurs independently and with co-existent Alzheimer’s disease (AD) and small vessel disease. We compared diffusion tensor imaging (DTI) metrics of the fornix, the primary efferent tract of the hippocampus between CAA, AD and Mild Cognitive Impairment (MCI) and healthy controls. Methods Sixty-eight healthy controls, 32 CAA, 21 AD, and 26 MCI patients were recruited at two centers. Diffusion tensor images were acquired at 3 T with high spatial resolution and fluid-attenuated inversion recovery (FLAIR) to suppress cerebrospinal fluid (CSF) and minimize partial volume effects on the fornix. The fornix was delineated with deterministic tractography to yield mean diffusivity (MD), axial diffusivity (AXD), radial diffusivity (RD), fractional anisotropy (FA) and tract volume. Volumetric measurements of the hippocampus, thalamus, and lateral ventricles were obtained using T1-weighted MRI. Results Diffusivity (MD, AXD, and RD) of the fornix was highest in AD followed by CAA compared to controls; the MCI group was not significantly different from controls. FA was similar between groups. Fornix tract volume was ∼ 30% lower for all three patient groups compared to controls, but not significantly different between the patient groups. Thalamic and hippocampal volumes were preserved in CAA, but lower in AD and MCI compared to controls. Lateral ventricular volumes were increased in CAA, AD and MCI. Global cognition, memory, and executive function all correlated negatively with fornix diffusivity across the combined clinical group. Conclusion There were significant diffusion changes of the fornix in CAA, AD and MCI compared to controls, despite relatively intact thalamic and hippocampal volumes in CAA, suggesting the mechanisms for fornix diffusion abnormalities may differ in CAA compared to AD and MCI.
Collapse
Affiliation(s)
- Ibrahim Shaikh
- Department of Medicine, Division of Neurology and Neuroscience and Mental Health Institute (NMHI), University of Alberta, Edmonton, AB, Canada; Department of Biomedical Engineering, University of Alberta, Edmonton, AB, Canada
| | - Christian Beaulieu
- Department of Biomedical Engineering, University of Alberta, Edmonton, AB, Canada
| | - Myrlene Gee
- Department of Medicine, Division of Neurology and Neuroscience and Mental Health Institute (NMHI), University of Alberta, Edmonton, AB, Canada
| | - Cheryl R McCreary
- Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Seaman Family MR Research Centre, Foothills Medical Centre, Alberta Health Services, Calgary, AB, Canada
| | - Andrew E Beaudin
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
| | - Diana Valdés-Cabrera
- Department of Biomedical Engineering, University of Alberta, Edmonton, AB, Canada
| | - Eric E Smith
- Department of Radiology, University of Calgary, Calgary, AB, Canada; Seaman Family MR Research Centre, Foothills Medical Centre, Alberta Health Services, Calgary, AB, Canada
| | - Richard Camicioli
- Department of Medicine, Division of Neurology and Neuroscience and Mental Health Institute (NMHI), University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
5
|
Rivas-Fernández MÁ, Lindín M, Zurrón M, Díaz F, Aldrey-Vázquez JM, Pías-Peleteiro JM, Vázquez-Vázquez L, Pereiro AX, Lojo-Seoane C, Nieto-Vieites A, Galdo-Álvarez S. Brain Atrophy and Clinical Characterization of Adults With Mild Cognitive Impairment and Different Cerebrospinal Fluid Biomarker Profiles According to the AT(N) Research Framework of Alzheimer’s Disease. Front Hum Neurosci 2022; 16:799347. [PMID: 35280203 PMCID: PMC8914376 DOI: 10.3389/fnhum.2022.799347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 01/10/2022] [Indexed: 12/05/2022] Open
Abstract
Introduction This study aimed to evaluate, in adults with mild cognitive impairment (MCI), the brain atrophy that may distinguish between three AT(N) biomarker-based profiles, and to determine its clinical value. Methods Structural MRI (sMRI) was employed to evaluate the volume and cortical thickness differences in MCI patients with different AT(N) profiles, namely, A−T−(N)−: normal AD biomarkers; A+T−(N)−: AD pathologic change; and A+T+(N)+: prodromal AD. Sensitivity and specificity of these changes were also estimated. Results An initial atrophy in medial temporal lobe (MTL) areas was found in the A+T−(N)− and A+T+(N)+ groups, spreading toward the parietal and frontal regions in A+T+(N)+ patients. These structural changes allowed distinguishing AT(N) profiles within the AD continuum; however, the profiles and their pattern of neurodegeneration were unsuccessful to determine the current clinical status. Conclusion sMRI is useful in the determination of the specific brain structural changes of AT(N) profiles along the AD continuum, allowing differentiation between MCI adults with or without pathological AD biomarkers.
Collapse
Affiliation(s)
- Miguel Ángel Rivas-Fernández
- Department of Clinical Psychology and Psychobiology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- *Correspondence: Miguel Ángel Rivas-Fernández,
| | - Mónica Lindín
- Department of Clinical Psychology and Psychobiology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Montserrat Zurrón
- Department of Clinical Psychology and Psychobiology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Fernando Díaz
- Department of Clinical Psychology and Psychobiology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - José Manuel Aldrey-Vázquez
- Neurology Service, Santiago Clinic Hospital (CHUS), Santiago de Compostela, Spain
- NeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Juan Manuel Pías-Peleteiro
- Neurology Service, Santiago Clinic Hospital (CHUS), Santiago de Compostela, Spain
- NeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Laura Vázquez-Vázquez
- NeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Arturo Xosé Pereiro
- Department of Developmental and Educational Psychology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Cristina Lojo-Seoane
- Department of Developmental and Educational Psychology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Ana Nieto-Vieites
- Department of Developmental and Educational Psychology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Santiago Galdo-Álvarez
- Department of Clinical Psychology and Psychobiology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| |
Collapse
|
6
|
Souto JJ, Silva GM, Almeida NL, Shoshina II, Santos NA, Fernandes TP. Age-related episodic memory decline and the role of amyloid-β: a systematic review. Dement Neuropsychol 2021; 15:299-313. [PMID: 34630918 PMCID: PMC8485646 DOI: 10.1590/1980-57642021dn15-030002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Accepted: 02/22/2021] [Indexed: 12/25/2022] Open
Abstract
Aging has been associated with the functional decline of episodic memory (EM). Unanswered questions are whether the decline of EM occurs even during healthy aging and whether this decline is related to amyloid-β (Aβ) deposition in the hippocampus. Objective The main purpose of this study was to investigate data on the relationship between the age-related EM decline and Aβ deposition. Methods We searched the Cochrane, MEDLINE, Scopus, and Web of Science databases and reference lists of retrieved articles that were published in the past 10 years. The initial literature search identified 517 studies. After screening the title, abstract, key words, and reference lists, 56 studies met the inclusion criteria. Results The overall results revealed that increases in Aβ are related to lower hippocampal volume and worse performance on EM tests. The results of this systematic review revealed that high levels of Aβ may be related to EM deficits and the progression to Alzheimer's disease. Conclusions We discussed the strengths and pitfalls of various tests and techniques used for investigating EM and Aβ deposition, methodological issues, and potential directions for future research.
Collapse
Affiliation(s)
- Jandirlly Julianna Souto
- Department of Psychology, Universidade Federal da Paraíba - João Pessoa, PB, Brazil.,Perception, Neuroscience and Behaviour Laboratory, Universidade Federal da Paraíba - João Pessoa, Brazil
| | - Gabriella Medeiros Silva
- Department of Psychology, Universidade Federal da Paraíba - João Pessoa, PB, Brazil.,Perception, Neuroscience and Behaviour Laboratory, Universidade Federal da Paraíba - João Pessoa, Brazil
| | - Natalia Leandro Almeida
- Department of Psychology, Universidade Federal da Paraíba - João Pessoa, PB, Brazil.,Perception, Neuroscience and Behaviour Laboratory, Universidade Federal da Paraíba - João Pessoa, Brazil
| | | | - Natanael Antonio Santos
- Department of Psychology, Universidade Federal da Paraíba - João Pessoa, PB, Brazil.,Perception, Neuroscience and Behaviour Laboratory, Universidade Federal da Paraíba - João Pessoa, Brazil
| | - Thiago Paiva Fernandes
- Department of Psychology, Universidade Federal da Paraíba - João Pessoa, PB, Brazil.,Perception, Neuroscience and Behaviour Laboratory, Universidade Federal da Paraíba - João Pessoa, Brazil
| |
Collapse
|
7
|
Rodriguez-Vieitez E, Montal V, Sepulcre J, Lois C, Hanseeuw B, Vilaplana E, Schultz AP, Properzi MJ, Scott MR, Amariglio R, Papp KV, Marshall GA, Fortea J, Johnson KA, Sperling RA, Vannini P. Association of cortical microstructure with amyloid-β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. Mol Psychiatry 2021; 26:7813-7822. [PMID: 34588623 PMCID: PMC8873001 DOI: 10.1038/s41380-021-01290-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 08/16/2021] [Accepted: 09/03/2021] [Indexed: 02/07/2023]
Abstract
Noninvasive biomarkers of early neuronal injury may help identify cognitively normal individuals at risk of developing Alzheimer's disease (AD). A recent diffusion-weighted imaging (DWI) method allows assessing cortical microstructure via cortical mean diffusivity (cMD), suggested to be more sensitive than macrostructural neurodegeneration. Here, we aimed to investigate the association of cMD with amyloid-β and tau pathology in older adults, and whether cMD predicts longitudinal cognitive decline, neurodegeneration and clinical progression. The study sample comprised n = 196 cognitively normal older adults (mean[SD] 72.5 [9.4] years; 114 women [58.2%]) from the Harvard Aging Brain Study. At baseline, all participants underwent structural MRI, DWI, 11C-Pittsburgh compound-B-PET, 18F-flortaucipir-PET imaging, and cognitive assessments. Longitudinal measures of Preclinical Alzheimer Cognitive Composite-5 were available for n = 186 individuals over 3.72 (1.96)-year follow-up. Prospective clinical follow-up was available for n = 163 individuals over 3.2 (1.7) years. Surface-based image analysis assessed vertex-wise relationships between cMD, global amyloid-β, and entorhinal and inferior-temporal tau. Multivariable regression, mixed effects models and Cox proportional hazards regression assessed longitudinal cognition, brain structural changes and clinical progression. Tau, but not amyloid-β, was positively associated with cMD in AD-vulnerable regions. Correcting for baseline demographics and cognition, increased cMD predicted steeper cognitive decline, which remained significant after correcting for amyloid-β, thickness, and entorhinal tau; there was a synergistic interaction between cMD and both amyloid-β and tau on cognitive slope. Regional cMD predicted hippocampal atrophy rate, independently from amyloid-β, tau, and thickness. Elevated cMD predicted progression to mild cognitive impairment. Cortical microstructure is a noninvasive biomarker that independently predicts subsequent cognitive decline, neurodegeneration and clinical progression, suggesting utility in clinical trials.
Collapse
Affiliation(s)
- Elena Rodriguez-Vieitez
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.509504.d0000 0004 0475 2664Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA USA ,grid.4714.60000 0004 1937 0626Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
| | - Victor Montal
- grid.7080.f0000 0001 2296 0625Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain ,grid.418264.d0000 0004 1762 4012Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Jorge Sepulcre
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.512020.4Gordon Center for Medical Imaging, Boston, MA USA
| | - Cristina Lois
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.512020.4Gordon Center for Medical Imaging, Boston, MA USA
| | - Bernard Hanseeuw
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.512020.4Gordon Center for Medical Imaging, Boston, MA USA ,grid.7942.80000 0001 2294 713XSaint Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium
| | - Eduard Vilaplana
- grid.7080.f0000 0001 2296 0625Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain ,grid.418264.d0000 0004 1762 4012Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Aaron P. Schultz
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.509504.d0000 0004 0475 2664Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA USA
| | - Michael J. Properzi
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA
| | - Matthew R. Scott
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.509504.d0000 0004 0475 2664Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA USA
| | - Rebecca Amariglio
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.38142.3c000000041936754XBrigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Kathryn V. Papp
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.509504.d0000 0004 0475 2664Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA USA ,grid.38142.3c000000041936754XBrigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Gad A. Marshall
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.509504.d0000 0004 0475 2664Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA USA ,grid.38142.3c000000041936754XBrigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Juan Fortea
- grid.7080.f0000 0001 2296 0625Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain ,grid.418264.d0000 0004 1762 4012Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Keith A. Johnson
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.512020.4Gordon Center for Medical Imaging, Boston, MA USA
| | - Reisa A. Sperling
- grid.38142.3c000000041936754XMassachusetts General Hospital, Harvard Medical School, Boston, MA USA ,grid.509504.d0000 0004 0475 2664Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA USA ,grid.38142.3c000000041936754XBrigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Patrizia Vannini
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. .,Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, USA. .,Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
8
|
Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Neurobiol Aging 2020; 100:22-31. [PMID: 33461049 DOI: 10.1016/j.neurobiolaging.2020.12.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 11/23/2020] [Accepted: 12/08/2020] [Indexed: 01/06/2023]
Abstract
Some studies suggest that angiotensin II type 1 receptor blockers (ARBs) may protect against memory decline more than angiotensin-converting enzyme inhibitors (ACE-Is), but few have examined possible mechanisms. We assessed longitudinal differences between ARB versus ACE-I users in global and sub-regional amyloid-β accumulation by 18F-florbetapir. In cognitively normal older adults (n= 142), propensity-weighted linear mixed-effects models showed that ARB versus ACE-I use was associated with slower amyloid-β accumulation in the cortex, and specifically in the caudal anterior cingulate and precuneus, and in the precentral and postcentral gyri. In amyloid-positive participants with Alzheimer's disease dementia or mild cognitive impairment (n = 169), ARB versus ACE-I use was not associated with different rates of amyloid-β accumulation. Apolipoprotein E ε4 carrier status explained some heterogeneity in the different rates of amyloid-β accumulation between users of ARBs versus ACE-Is in the study. Replicative studies and clinical trials are warranted to confirm potential benefits of ARBs on rates of amyloid-β accumulation in the contexts of Alzheimer's disease prevention and treatment.
Collapse
|
9
|
Srisaikaew P, Wongpakaran N, Anderson ND, Chen JJ, Kothan S, Varnado P, Unsrisong K, Mahakkanukrauh P. Fornix Integrity Is Differently Associated With Cognition in Healthy Aging and Non-amnestic Mild Cognitive Impairment: A Pilot Diffusion Tensor Imaging Study in Thai Older Adults. Front Aging Neurosci 2020; 12:594002. [PMID: 33343334 PMCID: PMC7745667 DOI: 10.3389/fnagi.2020.594002] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Accepted: 11/02/2020] [Indexed: 02/05/2023] Open
Abstract
Damage to the fornix leads to significant memory impairment and executive dysfunction and is associated with dementia risk. We sought to identify if fornix integrity and fiber length are disrupted in mild cognitive impairment (MCI) and how they associate with cognition. Data from 14 healthy older adult controls (HCs) and 17 subjects with non-amnestic MCI (n-aMCI) were analyzed. Diffusion tensor imaging (DTI) at 1.5 Tesla MRI was performed to enable manual tracing of the fornix and calculation of DTI parameters. Higher fractional anisotropy of body and column of the fornix was associated with better executive functioning and memory, more strongly in the HC than in the n-aMCI group. Fornix fiber tract length (FTL) was associated with better executive function, more strongly in the n-aMCI than in the HC group, and with better memory, more strongly in the HC than in the n-aMCI group. These results highlight a decline in the contributions of the fornix to cognition in n-aMCI and suggest that maintenance of fornix FTL is essential for sustaining executive functioning in people with n-aMCI.
Collapse
Affiliation(s)
- Patcharaporn Srisaikaew
- Ph.D. Program in Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
- Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Nahathai Wongpakaran
- Geriatric Psychiatry Unit, Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Nicole D. Anderson
- Rotman Research Institute, Baycrest Health Science, Toronto, ON, Canada
- Department of Psychology and Psychiatry, University of Toronto, Toronto, ON, Canada
| | - J. Jean Chen
- Rotman Research Institute, Baycrest Health Science, Toronto, ON, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
| | - Suchart Kothan
- Department of Radiologic Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
| | - Pairada Varnado
- Geriatric Psychiatry Unit, Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Kittisak Unsrisong
- Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Pasuk Mahakkanukrauh
- Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
- Excellence in Osteology Research and Training Center (ORTC), Chiang Mai University, Chiang Mai, Thailand
| |
Collapse
|
10
|
White matter pathways underlying Chinese semantic and phonological fluency in mild cognitive impairment. Neuropsychologia 2020; 149:107671. [PMID: 33189733 DOI: 10.1016/j.neuropsychologia.2020.107671] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 11/01/2020] [Accepted: 11/02/2020] [Indexed: 12/21/2022]
Abstract
Neuroimaging evidence has suggested that Chinese-language processing differs from that of its alphabetic-language counterparts. However, the underlying white matter pathway correlations between semantic and phonological fluency in Chinese-language processing remain unknown. Thus, we investigated the differences between two verbal fluency tests on 50 participants with amnestic mild cognitive impairment (aMCI) and 36 healthy controls (HC) with respect to five groups (ventral and dorsal stream fibers, frontal-striatal fibers, hippocampal-related fibers, and the corpus callosum) of white matter microstructural integrity. Diffusion spectrum imaging was used. The results revealed a progressive reduction in advantage in semantic fluency relative to phonological fluency from HC to single-domain aMCI to multidomain aMCI. Common and dissociative white matter correlations between tests of the two types of fluency were identified. Both types of fluency relied on the corpus callosum and ventral stream fibers, semantic fluency relied on the hippocampal-related fibers, and phonological fluency relied on the dorsal stream and frontal-striatal fibers. The involvement of bilateral tracts of interest as well as the association with the corpus callosum indicate the uniqueness of Chinese-language fluency processing. Dynamic associations were noted between white matter tract involvement and performance on the two fluency tests in four time blocks. Overall, our findings suggest the clinical utility of verbal fluency tests in geriatric populations, and they elucidate both task-specific and language-specific brain-behavior associations.
Collapse
|
11
|
Falangola MF, Nie X, Ward R, McKinnon ET, Dhiman S, Nietert PJ, Helpern JA, Jensen JH. Diffusion MRI detects early brain microstructure abnormalities in 2-month-old 3×Tg-AD mice. NMR IN BIOMEDICINE 2020; 33:e4346. [PMID: 32557874 PMCID: PMC7683375 DOI: 10.1002/nbm.4346] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 05/08/2020] [Accepted: 05/20/2020] [Indexed: 06/11/2023]
Abstract
The 3×Tg-AD mouse is one of the most studied animal models of Alzheimer's disease (AD), and develops both amyloid beta deposits and neurofibrillary tangles in a temporal and spatial pattern that is similar to human AD pathology. Additionally, abnormal myelination patterns with changes in oligodendrocyte and myelin marker expression are reported to be an early pathological feature in this model. Only few diffusion MRI (dMRI) studies have investigated white matter abnormalities in 3×Tg-AD mice, with inconsistent results. Thus, the goal of this study was to investigate the sensitivity of dMRI to capture brain microstructural alterations in 2-month-old 3×Tg-AD mice. In the fimbria, the fractional anisotropy (FA), kurtosis fractional anisotropy (KFA), and radial kurtosis (K┴ ) were found to be significantly lower in 3×Tg-AD mice than in controls, while the mean diffusivity (MD) and radial diffusivity (D┴ ) were found to be elevated. In the fornix, K┴ was lower for 3×Tg-AD mice; in the dorsal hippocampus MD and D┴ were elevated, as were FA, MD, and D┴ in the ventral hippocampus. These results indicate, for the first time, dMRI changes associated with myelin abnormalities in young 3×Tg-AD mice, before they develop AD pathology. Morphological quantification of myelin basic protein immunoreactivity in the fimbria was significantly lower in the 3×Tg-AD mice compared with the age-matched controls. Our results demonstrate that dMRI is able to detect widespread, significant early brain morphological abnormalities in 2-month-old 3×Tg-AD mice.
Collapse
Affiliation(s)
- Maria Fatima Falangola
- Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina, US
- Center for Biomedical Imaging, Medical University of South Carolina, Charleston, South Carolina, US
| | - Xingju Nie
- Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina, US
- Center for Biomedical Imaging, Medical University of South Carolina, Charleston, South Carolina, US
| | - Ralph Ward
- Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, US
| | - Emilie T McKinnon
- Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina, US
- Department of Neurology, Medical University of South Carolina, Charleston, South Carolina, US
| | - Siddhartha Dhiman
- Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina, US
| | - Paul J Nietert
- Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, US
| | - Joseph A Helpern
- Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina, US
- Center for Biomedical Imaging, Medical University of South Carolina, Charleston, South Carolina, US
| | - Jens H Jensen
- Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina, US
- Center for Biomedical Imaging, Medical University of South Carolina, Charleston, South Carolina, US
- Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, South Carolina, US
| |
Collapse
|
12
|
Rabin JS, Neal TE, Nierle HE, Sikkes SAM, Buckley RF, Amariglio RE, Papp KV, Rentz DM, Schultz AP, Johnson KA, Sperling RA, Hedden T. Multiple markers contribute to risk of progression from normal to mild cognitive impairment. NEUROIMAGE-CLINICAL 2020; 28:102400. [PMID: 32919366 PMCID: PMC7491146 DOI: 10.1016/j.nicl.2020.102400] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 08/17/2020] [Accepted: 08/25/2020] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To identify a parsimonious set of markers that optimally predicts subsequent clinical progression from normal to mild cognitive impairment (MCI). METHODS 250 clinically normal adults (mean age = 73.6 years, SD = 6.0) from the Harvard Aging Brain Study were assessed at baseline on a wide set of markers, including magnetic resonance imaging markers of gray matter thickness and volume, white matter lesions, fractional anisotropy, resting state functional connectivity, positron emission tomography markers of glucose metabolism and β-amyloid (Aβ) burden, and a measure of vascular risk. Participants were also tested annually on a battery of clinical and cognitive tests (median follow-up = 5.0 years, SD = 1.66). We applied least absolute shrinkage and selection operator (LASSO) Cox models to determine the minimum set of non-redundant markers that predicts subsequent clinical progression from normal to MCI, adjusting for age, sex, and education. RESULTS 23 participants (9.2%) progressed to MCI over the study period (mean years of follow-up to diagnosis = 3.96, SD = 1.89). Progression was predicted by several brain markers, including reduced entorhinal thickness (hazard ratio, HR = 1.73), greater Aβ burden (HR = 1.58), lower default network connectivity (HR = 1.42), and smaller hippocampal volume (HR = 1.30). When cognitive test scores were added to the model, the aforementioned neuroimaging markers remained significant and lower striatum volume as well as lower scores on baseline memory and processing speed tests additionally contributed to progression. CONCLUSION Among a large set of brain, vascular and cognitive markers, a subset of markers independently predicted progression from normal to MCI. These markers may enhance risk stratification by identifying clinically normal individuals who are most likely to develop clinical symptoms and would likely benefit most from therapeutic intervention.
Collapse
Affiliation(s)
- Jennifer S Rabin
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA; Harquail Centre for Neuromodulation and Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada; Department of Medicine (Neurology), University of Toronto, Toronto, ON M5S 3H2, Canada
| | - Taylor E Neal
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Hannah E Nierle
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Sietske A M Sikkes
- Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, The Netherlands; Department of Epidemiology and Biostatistics, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA
| | - Rachel F Buckley
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA; Florey Institutes of Neuroscience and Mental Health, Melbourne and Melbourne School of Psychological Science, University of Melbourne, Melbourne, Australia; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Rebecca E Amariglio
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Kathryn V Papp
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Dorene M Rentz
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Aaron P Schultz
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
| | - Keith A Johnson
- Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA; Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, MA 02144, USA
| | - Reisa A Sperling
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
| | - Trey Hedden
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
| |
Collapse
|
13
|
Benear SL, Ngo CT, Olson IR. Dissecting the Fornix in Basic Memory Processes and Neuropsychiatric Disease: A Review. Brain Connect 2020; 10:331-354. [PMID: 32567331 DOI: 10.1089/brain.2020.0749] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background: The fornix is the primary axonal tract of the hippocampus, connecting it to modulatory subcortical structures. This review reveals that fornix damage causes cognitive deficits that closely mirror those resulting from hippocampal lesions. Methods: We reviewed the literature on the fornix, spanning non-human animal lesion research, clinical case studies of human patients with fornix damage, as well as diffusion-weighted imaging (DWI) work that evaluates fornix microstructure in vivo. Results: The fornix is essential for memory formation because it serves as the conduit for theta rhythms and acetylcholine, as well as providing mnemonic representations to deep brain structures that guide motivated behavior, such as when and where to eat. In rodents and non-human primates, fornix lesions lead to deficits in conditioning, reversal learning, and navigation. In humans, damage to the fornix manifests as anterograde amnesia. DWI research reveals that the fornix plays a key role in mild cognitive impairment and Alzheimer's Disease, and can potentially predict conversion from the former to the latter. Emerging DWI findings link perturbations in this structure to schizophrenia, mood disorders, and eating disorders. Cutting-edge research has investigated how deep brain stimulation of the fornix can potentially attenuate memory loss, control epileptic seizures, and even improve mood. Conclusions: The fornix is essential to a fully functioning memory system and is implicated in nearly all neurological functions that rely on the hippocampus. Future research needs to use optimized DWI methods to study the fornix in vivo, which we discuss, given the difficult nature of fornix reconstruction. Impact Statement The fornix is a white matter tract that connects the hippocampus to several subcortical brain regions and is pivotal for episodic memory functioning. Functionally, the fornix transmits essential neurotransmitters, as well as theta rhythms, to the hippocampus. In addition, it is the conduit by which memories guide decisions. The fornix is biomedically important because lesions to this tract result in irreversible anterograde amnesia. Research using in vivo imaging methods has linked fornix pathology to cognitive aging, mild cognitive impairment, psychosis, epilepsy, and, importantly, Alzheimer's Disease.
Collapse
Affiliation(s)
- Susan L Benear
- Department of Psychology, Temple University, Philadelphia, Pennsylvania, USA
| | - Chi T Ngo
- Center for Lifespan Psychology, Max Planck Institute for Human Development, Berlin, Germany
| | - Ingrid R Olson
- Department of Psychology, Temple University, Philadelphia, Pennsylvania, USA
| |
Collapse
|
14
|
Christidi F, Karavasilis E, Rentzos M, Velonakis G, Zouvelou V, Xirou S, Argyropoulos G, Papatriantafyllou I, Pantolewn V, Ferentinos P, Kelekis N, Seimenis I, Evdokimidis I, Bede P. Hippocampal pathology in amyotrophic lateral sclerosis: selective vulnerability of subfields and their associated projections. Neurobiol Aging 2019; 84:178-188. [DOI: 10.1016/j.neurobiolaging.2019.07.019] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Revised: 07/10/2019] [Accepted: 07/10/2019] [Indexed: 12/29/2022]
|